What's happening
Writing a plain-English summary… Track this bill to get it by email.
Why it matters
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
Headline styles
Sponsors
History
- Referred to insurance
- Referred to insurance
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Requires insurance coverage for the HALO breast pap test to detect risk of developing breast cancer
In Assembly Committee · Insurance · Sponsor Aileen Gunther
Full text
The text isn't available here yet. Check nysenate.gov.
Sponsor's memo
BILL NUMBER:S3454
Title of bill
An act to amend the insurance law, in relation to coverage for the HALO breast pap test to detect risk of developing breast cancer
Purpose
To require insurance coverage for the HALO breast pap test to detect risk of developing breast cancer.
Summary of provisions
Section 1 amends subsection (i) of section 3216 of the insurance law by adding a new paragraph 32 which requires every policy which provides coverage for hospital, surgical, or medical care coverage also provide coverage for the HALO breast pap test, when such test is recommended by a physician.
Section 2 amends subsection (1) of section 3221 of the insurance law by adding a new paragraph 19 which requires any group or blanket accident or health insurance policy or issuing a group blanket policy for delivery in this state which provides coverage for hospital, surgical, or medical care coverage also provide coverage for the HALO breast pap test, when such test is recommended by a physician.
Section 3 amends section 4303 of the insurance law by adding a new subsection (pp) which requires any medical expense indemnity corporation, hospital service corporation or a health service corporation which provides coverage for hospital, surgical, or medical care coverage also provide coverage for the HALO breast pap test, when such test is recommended by a physician.
Section 4 is the effective date.
Justification
HALO is the only FDA-cleared risk assessment tool for non-hereditary breast cancer. By collecting nipple aspirate fluid (NAF) for cytological evaluation, HALO helps identify precancerous changes at the cellular level years before a potentially cancerous lesion might form. Multiple clinical studies concur that women with these cellular abnormalities are four to five times more likely to develop future breast cancer.
One in eight women will develop breast cancer in her lifetime, but to date, ifs been very difficult to identify who is at risk, so we wait for lumps before intervening. Traditional methods of breast cancer screening, mammograms and breast exams, find cancers that have been growing, on average, for eight to ten years. Also, standard film mammography is not as effective in women under 50 with dense breasts, and misses up to 73 percent of cancers in this group, which is one reason for the recent controversy over its use. HALO is a risk assessment tool that can help identify women at greatest risk, years earlier, allowing for earlier intervention and increasing chances for prevention and survival. Knowing who is at greatest risk helps us focus or a limited resources on the right women.
Legislative history
2013-14 - died in Insurance Committee in both Houses.
Fiscal implications
None
Effective date
This act shall take effect on the first of January next succeeding the date on which it shall become a law and apply to all policies or contracts issued, renewed, modified, altered or amended on and after such effective date.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.